Correction of Psoriatic T Cell Signatures by Deucravacitinib — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Correction of Psoriatic T Cell Signatures by Deucravacitinib — Stella

Recruiting

Back to Psoriasis Vulgaris trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

University of California, San Francisco, San Francisco, California

Key details

Phase

Post-approval study

Sponsor

University of California, San Francisco

Collaborators

Bristol-Myers Squibb

Enrollment target

~25 participants

Started

October 2023

Primary completion

June 2026

Age range

18 Years – 75 Years

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov